This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CP-868596
Description: CP-868,596 is a platelet derived growth factor receptor inhibitor (PDGFR).
Deal Structure: Pfizer and OSI entered into a Collaborative Research Agreement effective April 1, 1986. On April 1, 2001, the funded phase of thecollaborative research agreement expired and was not renewed. Following theexpiration of the collaborative research agreement, Pfizer is continuing todevelop certain specified drug candidates which emanated from the collaborativeresearch agreement. CP-868,596 was jointly discovered as result of the partnership; OSI will receive royalties from Pfizer if it is successful in commercializing the drug.
On March 1, 2010, Astellas Pharma announced they will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
On May 16, 2010, Astellas Pharma and OSI Pharmaceuticals announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI. Under the terms of the merger agreement,...See full deal structure in Biomedtracker
Partners: Astellas Pharma, Inc.
Pink Sheet Weekly Trademark Review Jan. 6, 2015
Pink Sheet Weekly Trademark Review Sept. 23, 2014
Pink Sheet Weekly Trademark Review Jan. 28, 2014
Pink Sheet Weekly Trademark Review Oct. 22, 2013
Additional information available to subscribers only: